Sotigalimab (APX005M) is a novel humanized anti-CD40 monoclonal antibody currently in Phase II clinical trials; it binds to CD40 on antigen-presenting cells, thereby enhancing immune responses by activating both innate and adaptive immune systems, and promoting multifaceted immune-mediated tumor cell killing.